Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2572733 | 0.97 | FAAH (0.48) | FAAHKDM4EALDH1A1LMNAHTT | |
| SCHEMBL2566826 | 0.94 | ALDH1A1 (0.49) | FAAHKDM4EALDH1A1LMNAHTT | |
| SCHEMBL2573830 | 0.85 | RXRA (0.53) | KDM4EALDH1A1LMNAHTTHDAC1 | |
| SCHEMBL2572335 | 0.84 | ALDH1A1 (0.59) | FAAHKDM4EALDH1A1LMNAHTT | |
| SCHEMBL10227120 | 0.81 | FAAH (0.64) | FAAHALDH1A1LMNAHDAC1SMN1; SMN2 | |
| SCHEMBL8212285 | 0.81 | RORC (0.49) | ALDH1A1LMNAHTTHDAC1AKT1 | |
| SCHEMBL8214975 | 0.81 | HDAC1 (0.50) | ALDH1A1LMNAHTTCTSKHDAC1 | |
| SCHEMBL2570917 | 0.81 | NPC1 (0.48) | ALDH1A1LMNAHTTCTSKHDAC1 | |
| SCHEMBL2571215 | 0.81 | ALDH1A1 (0.58) | FAAHKDM4EALDH1A1LMNAHTT | |
| SCHEMBL2573836 | 0.79 | HDAC1 (0.57) | HDAC1AKT1NAMPTL3MBTL1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | FAAH 2724/4885KDM4E 3863/4885ALDH1A1 1093/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | FAAH 2890/4885KDM4E 3787/4885ALDH1A1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.